Affimed N.V.

Affimed N.V.:
Proprietary ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive PTCL and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND cleared for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Im Neuenheimer Feld 582
Heidelberg, Baden-Wurttemberg 69120
Germany
Heidelberg, Baden-Wurttemberg 69120
Germany
Presentation:
More info:
My account:
Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13
- Adi Hoess, Ph.D., Chief Executive Officer
- Gregory Gin, Head of Investor Relations
Lead Programs
AFM13
Disease Target CD30 Immune Cell Target CD16A
Indication | Phase |
---|---|
Hodgkin lymphoma + PD-1 | 1 |
Hodgkin lymphoma | 2 |
Hodgkin lymphoma + adoptive NK cells | Pre-clinical |
CD30-positive lymphoma | 2 |
AFM24
Disease Target EGFRwt Immune Cell Target CD16A
Indication | Phase |
---|---|
Solid tumors | Pre-clinical |
Top 10 Holders of Affimed N.V.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
NEA Management Co. | 8.04 | 6,126,488 | 37.86 | 13F | 9/30/20 |
Millennium Management LLC | 5.57 | 4,246,451 | 26.24 | 13F | 9/30/20 |
683 Capital Management LLC | 4.79 | 3,650,000 | 22.56 | 13F | 9/30/20 |
BlackRock Fund Advisors | 4.41 | 3,360,265 | 20.77 | 13F | 9/30/20 |
Citadel LP | 4.16 | 3,173,215 | 19.61 | 13F | 9/30/20 |
Bain Capital Public Equity Management II LLC | 2.82 | 2,148,513 | 13.28 | 13F | 9/30/20 |
Point72 Asset Management LP (Old) | 2.62 | 2,000,000 | 12.36 | 13F | 9/30/20 |
Acadian Asset Management LLC | 2.49 | 1,900,379 | 11.74 | 13F | 9/30/20 |
State Street Corp. | 2.08 | 1,589,594 | 9.82 | 13F | 9/30/20 |
Eversept Partners LP | 1.63 | 1,245,458 | 7.70 | 13F | 9/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.